StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)

Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –

Niagen Bioscience total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Niagen Bioscience's total debt was $137.00K at Dec 31, 2018. For fiscal 2018 it was $137.00K, down 55.8% from the year before. The highest annual figure on record is $4.87M in fiscal 2015.

Annual total debt

PeriodPeriod endValueChange
FY2018Dec 31, 2018$137.00K-55.8%
FY2017Dec 30, 2017$310.00K–
FY2016Dec 31, 2016$0-100.0%
FY2015Jan 2, 2016$4.87M+121.5%
FY2014Jan 3, 2015$2.20M+684.9%
FY2013Dec 28, 2013$280.34K+88.9%
FY2012Dec 29, 2012$148.37K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2018Dec 31, 2018$137.00K–
Q4 FY2017Dec 30, 2017$310.00K–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Oct 1, 2016$0–

More Niagen Bioscience figures

See a number that looks wrong?